Navigation Links
AEterna Zentaris: New Data Published on its Ghrelin Antagonist Compound, AEZS-123 (JMV2959), Supports its Use in Alcohol Addiction
Date:7/7/2009

ion said, "Ghrelin's action in the brain may be of importance for several addictions, including chemical drugs such as alcohol and even food."

Daniel Perrissoud, Senior Director of Project Management at AEterna Zentaris and one of the authors of the paper stated, "The discovery of the Gothenburg team that the reward system is a target of ghrelin effects, opens new development opportunities for our proprietary ghrelin receptor antagonists. In the field of addiction, the clinical proof of efficacy can be obtained in a more time- and cost-effective manner than in the field of obesity, as short-term clinical laboratory paradigms can be used for the clinical evaluation."

The article entitled, "Requirement of Central Ghrelin Signaling for Alcohol Reward" appears today in the July 7, 2009 issue of Proceedings of the National Academy of Sciences (PNAS 2009; 106:11318-11323) and was published on line on June 29, 2009 in the early edition of the journal.

About AEterna Zentaris' Ghrelin Antagonist Program

Ghrelin is a natural peptide hormone produced by the stomach that increases appetite and induces accumulation of fat tissue. The discovery of ghrelin and its receptors opens up new opportunities for the treatment of obesity and eating disorders through the use of ghrelin antagonists to suppress appetite and fat deposition.

In 2004, AEterna Zentaris signed two agreements for the development of ghrelin antagonists with the Institut des biomolecules Max Mousseron of the University of Montpellier, France, directed by Prof. Jean Martinez, and with the Department of Experimental and Environmental Medicine of the University of Milan, Italy, directed by Prof. Vittorio Locatelli. The research projects were targeting the chemical synthesis and pharmacological investigation of new compounds acting as ghrelin antagonists.

In 2006, AEterna Zentaris reported first in vivo pharmacological data on the capability of proprietary
'/>"/>

SOURCE AETERNA ZENTARIS INC.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. AEterna Zentaris completes management team with the appointment of Chief Medical Officer
2. AEterna Zentaris to Present at Upcoming UBS Global Life Sciences Conference in New York
3. AEterna Zentaris Announces Outcome of Managements Strategic Review
4. AEterna Zentaris to Further Develop Three Follow-up Multi-targeted Cytotoxic Candidates to AEZS-112 as Potential Novel Cancer Treatment
5. AEterna Zentaris Reports First Patients Treated with Anti-Cancer Compound AEZS-108 in Phase 2 Trial in Ovarian and Endometrial Cancers
6. AEterna Zentaris to Present at the Upcoming Roth Capital Partners 20th Annual OC Growth Stock Conference in Dana Point, California
7. Aeterna Zentaris to Announce Fourth Quarter and Full-Year 2007 Financial and Operating Results on March 5, 2008
8. AEterna Zentaris Announces the Departure of SVP, Administrative and Legal Affairs
9. AEterna Zentaris and Paladin Labs Announce Sale and Purchase of Miltefosine Rights
10. Aeterna Zentaris Reports Fourth Quarter and Full-Year 2007 Financial and Operating Results
11. Aeterna Zentaris Begins Second Phase 3 Trial of Cetrorelix for Benign Prostatic Hyperplasia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... , March 27, 2015   SurePure, Inc ... photopurification, announced today that the Company has completed ... continued trading of SurePure ("SURP") securities on OTCQB, ... for entrepreneurial and development stage companies. ... standards and eligibility requirements designed to improve marketplace ...
(Date:3/27/2015)... 27, 2015  CASI Pharmaceuticals, Inc. (Nasdaq: CASI ... and commercialization of innovative therapeutics addressing cancer and other ... commercial focus on China , today ... ended December 31, 2014.  The Company ... per share, for the three months ended December 31, ...
(Date:3/26/2015)... TORONTO , March 26, 2015 /PRNewswire/ - SQI ... SQIDF) announced that after dealing with certain matters, including ... of shareholders held on March 26, 2015 (the "Meeting") ... until April 8, 2015 at 11:00 a.m. ( ... Meeting has been changed from that previous disclosed. The ...
(Date:3/26/2015)... 2015 Neogen Corporation (NASDAQ: NEOG ) ... quarter of fiscal 2015, which ended Feb. 28, increased ... $6,575,000. Earnings per share in the current quarter were ... net income increased 17% over prior year to $24,142,000, ... per share, for the same period a year ago. ...
Breaking Biology Technology:SurePure Completes Verification and Approved for Trading on the OTCQB Marketplace 2CASI Pharmaceuticals Reports 2014 Fourth Quarter And Full Year Financial Results 2CASI Pharmaceuticals Reports 2014 Fourth Quarter And Full Year Financial Results 3CASI Pharmaceuticals Reports 2014 Fourth Quarter And Full Year Financial Results 4CASI Pharmaceuticals Reports 2014 Fourth Quarter And Full Year Financial Results 5CASI Pharmaceuticals Reports 2014 Fourth Quarter And Full Year Financial Results 6SQI Diagnostics Inc. Announces Adjournment of Meeting 2Neogen reports 13% increase in net income 2Neogen reports 13% increase in net income 3Neogen reports 13% increase in net income 4Neogen reports 13% increase in net income 5Neogen reports 13% increase in net income 6Neogen reports 13% increase in net income 7Neogen reports 13% increase in net income 8
... March 11 Indevus,Pharmaceuticals, Inc. (Nasdaq: IDEV ) ... and Company 28th Annual Health Care Conference, on,Tuesday, March ... being held in,Boston, Massachusetts. The presentation will be web ... section of the Indevus website at, http://www.indevus.com ., ...
... Lett, CEO of The,BioAnalytics Group LLC and Ned ... Tucson Symposium on March 12-13, 2008. The,symposium, subtitled, ... Diagnostics," will be attended by hundreds of,scientists and ... Dr. Lett,s invited presentation will focus on ...
... France, March 11 Transgene,(Euronext Paris: FR0005175080) announces ... and outlook for 2008., "2007 was a ... the signing of a partnership agreement with Roche ... of diseases caused by the,HPV virus, and the ...
Cached Biology Technology:Indevus Pharmaceuticals to Present at Cowen and Company 28th Annual Health Care Conference 2Indevus Pharmaceuticals to Present at Cowen and Company 28th Annual Health Care Conference 3BioAnalytics Group CEO, Senior Scientist to Present at Tucson Symposium March 12-13 2Transgene in 2007: Partnership and Refinancing Position the Company for its Future Development 2Transgene in 2007: Partnership and Refinancing Position the Company for its Future Development 3Transgene in 2007: Partnership and Refinancing Position the Company for its Future Development 4Transgene in 2007: Partnership and Refinancing Position the Company for its Future Development 5Transgene in 2007: Partnership and Refinancing Position the Company for its Future Development 6Transgene in 2007: Partnership and Refinancing Position the Company for its Future Development 7Transgene in 2007: Partnership and Refinancing Position the Company for its Future Development 8Transgene in 2007: Partnership and Refinancing Position the Company for its Future Development 9Transgene in 2007: Partnership and Refinancing Position the Company for its Future Development 10Transgene in 2007: Partnership and Refinancing Position the Company for its Future Development 11Transgene in 2007: Partnership and Refinancing Position the Company for its Future Development 12
(Date:3/17/2015)... , March 17, 2015 ... company specializing in clinical study management systems, is ... in attendance at ARENA,s Outsourcing in Clinical Trials ... This event provides an excellent forum for MedNet ... flexible and affordable software-as-a-service (SaaS) eClinical technology platform. ...
(Date:3/12/2015)... FAIRFAX, Va. , March 12, 2015 ... company and a member of the Texas Instruments Design ... Chandrababu Naidu has demonstrated its IriShield USB MK2120U ... iris scanning facility for pension distribution. ... and assembled to be marketed in India ...
(Date:3/11/2015)... Mar. 11, 2015 Research and Markets ... "Access Control Market by Product, Application & By ... report to their offering. , This report ... reach $10.4 billion by 2020, with an estimated CAGR ... covers the products types such as contact cards & ...
Breaking Biology News(10 mins):Connect With MedNet Solutions At Outsourcing In Clinical Trials Southeast 2Indian States See IriTech's Scanner Bolstering Efficiency of Authentication for Aadhaar 2Indian States See IriTech's Scanner Bolstering Efficiency of Authentication for Aadhaar 3Global Access Control (Cards & Readers, Biometrics, Controllers, Management Software) Market 2015-2020 - Analysis of the $10 Billion Market 2
... planarian possesses an amazing ability to regenerate lost body parts. ... a complete planarian. The flatworm relies upon a population of ... light on how planarians maintain these stem cells throughout their ... issue of the journal Developmental Cell, scientists show that a ...
... By applying electrical currents across the heads of people while ... vestibular system helps us maintain upright posture; at the same ... in a way that allowed a person who was walking ... balance being affected. The findings are reported by Richard Fitzpatrick ...
... of us are familiar with the winding staircase image of ... But few of us realize just how tightly that famous ... a single molecule of human DNA extends more than three ... cell, that same molecule measures about one millionth of an ...
Cached Biology News:Scientists identify gene involved in stem cell self-renewal in planaria 2Stimulation of the semicircular canals can artificially control human walking and balance 2Surprise finding for stretched DNA 2Surprise finding for stretched DNA 3
Mouse monoclonal antibody raised against a partial recombinant DENR. NCBI Entrez Gene ID = DENR...
Mouse monoclonal antibody raised against a partial recombinant CRKRS. NCBI Entrez Gene ID = CRKRS...
... The BD PhosFlow Perm/Wash Buffer I can ... modified signaling proteins to permeabilize cells and ... cell wash buffer. Because saponin-mediated cell permeabilization ... to keep the cells in the presence ...
Mouse monoclonal antibody raised against a full length recombinant GPT. NCBI Entrez Gene ID = GPT...
Biology Products: